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Abstract
Background Although the prognostic value of Ki67 in
breast cancer is well documented, using optimal cut-points
for patient stratification, reproducibility of the scoring and
interpretation of the results remains a matter of debate
particularly when using tissue microarrays (TMAs). This
study aims to assess Ki67 expression assessed on TMAs
and their matched whole tissue sections (WTS). Moreover,
whether the cut-off used for WTS is reproducible on TMA
in BC molecular classes and the association between Ki67
expression cut-off, assessed on TMAs and WTS, and
clinicopathological parameters and patient outcome were
tested.
Method A large series (n = 707) of primary invasive
breast tumours were immunostained for Ki67 using both
TMA and WTS and assessed as percentage staining and
correlated with each other, clinicopathological parameters
and patient outcome. In addition, MKI67 mRNA expres-
sion was correlated with Ki67 protein levels on WTS and
TMAs in a subset of cases included in the METABRIC
study.
Results There was moderate concordance in Ki67 expres-
sion between WTS and TMA when analysed as a contin-
uous variable (Intraclass correlation coefficient = 0.61)
and low concordance when dichotomised (kappa
value = 0.3). TMA showed low levels of Ki67 with mean
percentage of expression of 35 and 22% on WTS and
TMA, respectively. MKI67 mRNA expression was signif-
icantly correlated with protein expression determined on
WTS (Spearman Correlation, r = 0.52) and to a lesser
extent on TMA (r = 0.34) (p\ 0.001). Regarding pre-
diction of patient outcome, statistically significant differ-
ences were detected upon stratification of patients with
tumours expressing Ki67 at 10, 15, 20, 25 or 30% in TMA.
Using TMA, C20% Ki67 provided the best prognostic cut-
off particularly in triple-negative and HER2-positive
classes.
Conclusion Ki67 expression in breast cancer can be eval-
uated using TMA although different cut-points are required
to emulate results from WTS. A cut-off of C20% for Ki67
expression in BC provides the best prognostic correlations
when TMAs are used.
Keywords Ki67  Breast Cancer  Immunohistochemistry 
Prognosis  METABRIC
Introduction
Ki67 has been extensively assessed and reported as a
prognostic and predictive marker in invasive breast cancer
(BC) [1–7]. High Ki67 expression in BC is associated with
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worse prognosis. In two meta-analyses published in 2007
and 2008, high Ki67 expression in both node-positive and
node-negative invasive BC showed significantly worse
overall and disease-free survival [8, 9]. Additionally,
results of a systematic review support the role of Ki67 as a
prognostic marker [10] and as an independent predictive
factor for neoadjuvant chemotherapy in BC patients
[5, 6, 11]. Furthermore, the St. Gallen consensus panel has
recommended Ki67 as a marker for the definition of
intrinsic BC subtypes to differentiate between luminal A
and luminal B subgroups [12, 13].
In clinical practice, the evaluation of prognostic/predic-
tive factors usually depends upon the stratification of the
patients into distinct risk groups based on the status of such
factor. The common approach is the choice of an optimal
cut-off point for the prognostic/predictive factor, assessed
as a continuous variable, e.g. percentage of cells stained, to
define these groups. The optimal cut-point for Ki67 in BC is
currently debatable despite the large number of published
studies reporting significant results [14, 15]. The recent
report on the second phase of the Ki67 trial reported that
there was a need to standardise the pre-analytical and ana-
lytical features for Ki67 immunohistochemistry, so that it
can be incorporated to drive patient-care decisions in clin-
ical practice [16]. In 2009, the St. Gallen panel proposed
that Ki67 expression should be stratified into three groups:
low\15%, intermediate 16–30% and high[30% [17].
This was based on univariate analysis carried out with
different Ki67 expression cut-points to find those best
stratifying the patients with lowest significant p values
according to survival using Ki67 immunoreactivity and
standardised mitotic index [18]. In 2011, St. Gallen rec-
ommended an alternative KI67 cut-point at 14% in order to
separate Oestrogen Receptor (ER)-positive tumours into
luminal A (\14%) and luminal B (C14%) [12]. This was
derived from comparison with gene array data as a prog-
nostic factor [19]. In 2013, St Gallen revised their threshold
to C20% for ‘high’ Ki67 status with the option to also use
locally specified cut-points [13]. Recently, at the 2015 St.
Gallen Breast Cancer Conference, a median cut-off value of
Ki67 within the range of 20–29% to differentiate ‘luminal
B-like’ has been recommended [20]. As shown by Urruti-
coechea et al. [21], up to 17 studies that included more than
200 patients displayed statistically significant association
between Ki67 and prognosis given that convincing evidence
for a biological relationship. However, the cut-offs to dis-
criminate a high from low level of Ki67 varied from 1 to
29%, consequently limiting its clinical utility. Furthermore,
during the past decade, multiple research studies have
additionally reported the assessment of Ki67 in BC using
tissue microarrays (TMA) platform [14] [15], although it
remains unclear as to their validity and comparison with
assessment in whole tissue sections (WTS).
In this study, we aim to assess BC proliferative fraction
using Ki67 assessment utilising matched cases prepared as
TMA and WTS taking into account the optimal cut-off
value for Ki67 assessed on TMA, the common method of
proliferation assessment in the research setting on large
cohorts. Herein we aimed at determining (1) to what extent
Ki67 protein as well as transcriptome levels are matched
between TMA and WTS; (2) whether the cut-point used for
WTS is reproducible using TMA in different molecular
classes. For the latter aim, the association between Ki67
expression cut-points assessed on TMAs and WTS and the
standard clinicopathological variables and patient outcome
was tested as endpoints.
Materials and methods
Patient cohort
This study was approved by the Nottingham Research
Ethics Committee 2 under the title ‘Development of a
molecular genetic classification of breast cancer’.
The expression of Ki67 was assessed on 707 cases of
invasive BC cases using WTS and TMA. TMAs were
prepared using 0.6-mm cores sampled from the invasive
tumour edge as previously described [22]. Cases were
derived from the retrospective Nottingham Tenovus Pri-
mary Breast Carcinoma Series. This is a consecutive well-
defined series of early-stage primary operable invasive BC
(TNM Stage I–III, excluding T3 and T4 tumours) from
patients presented to Nottingham City Hospital from 1988
to 1998. The age of the patients was B70 years (Supple-
mentary Table 1). Moreover, the clinical details of the
patients including age and menopausal status as well as the
tumour details including tumour size, grade, lymphovas-
cular invasion (LVI) and lymph node status were also
available and prospectively maintained. Survival data
include Breast Cancer-Specific Survival (BCSS), in
months, from the date the primary surgical treatment to the
time of death from breast cancer. Molecular classes were
defined as luminal (ER? and/or PR?),
HER2? (HER2? regardless of the expression of other
markers) and triple-negative (TN; HER2-, ER- and
PR-). In this cohort, transcriptomic data for MKI67 were
available for a subset (n = 101) from Nottingham cases
that were included in the METABRIC cohort [23].
Immunohistochemistry
4-lm sections were freshly cut from representative paraffin
blocks and transferred onto slides (Surgipath Xtra Adhe-
sive, Leica, Germany). Slides were incubated on a 60 C
hotplate for 10 min, followed by deparaffinisation and
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rehydration using xylene and graded alcohol. For antigen
retrieval, sections were incubated in Citrate Buffer at pH
6.0 for 20 min using microwave. Manual immunohisto-
chemistry staining was performed using either the Novo-
linkTM Max Polymer Detection Kit (Leica, Newcastle, UK)
for the TMAs and the standard streptavidin–biotin complex
method for the WTS following manufacturer’s instructions
and as previously described [4]. Optimised primary anti-
body, MIB-1 monoclonal mouse diluted 1:100 (Dako, Ref-
M7240) antibody was applied and incubated for 1 h at
room temperature. Finally, DAB chromogen reagent was
incubated for 5 min, then 0.1% Haematoxylin was added
as a counter stain. Dehydration, clearing, mounting and
cover-slipping were performed as previously described.
Human tonsil sections were used as a positive control,
while negative controls were performed by omitting the
application of primary antibody.
Ki67 assessment
Ki67-stained TMA slides were scanned into high-resolu-
tion digital images (0.45 lm/pixel) using a NanoZoomer
slide scanner (Hamamatsu Photonics Welwyn Garden City,
UK). Scoring of TMA was performed on digital images
using a web-based interface (Distiller, Slidepath Ltd.,
Dublin, Ireland). Only the invasive breast cancer cells
present in the TMA cores were assessed for Ki67 staining
and scored as a percentage of the positively stained nuclei
[15]. All tumour cell nuclei with homogenous granular
staining, multiple speckled staining or nucleolar staining
were regarded as positively stained regardless of their
staining intensity [24]. To test for inter-observer concor-
dance, three TMA slides (n = 350) were re-scored by
another observer (MA). Scoring of WTS was performed in
the areas with highest number of positive nuclei (hot spot)
within the invasive component of the tumour as previously
described [4]. Hot spots were identified by scanning the
section for immunostaining evaluation using a light
microscope at low power magnification (9100). Ki67 was
expressed as the percentage of positive malignant cells in
1000 malignant cells assessed under high power magnifi-
cation (9400). To assess for inter-observer concordance, a
subset of cases (n = 180) was re-scored by another
observer (AM).
Statistical analysis
Statistical analysis was performed using IBM SPSS soft-
ware version 22 (SPSS Inc., Chicago, IL, USA). For all
statistical tests a p value\ 0.05 was considered significant.
Spearman correlation test, Intraclass Correlation Coeffi-
cient (ICC) and kappa statistic were used to test the
reproducibility and the correlation between the Ki67
assessment between TMA and WTS. In kappa, complete
agreement is reflected by a value of 1.0 and only by chance
alone results in a value of zero. Although in the literature
there is no agreed standard criteria for kappa value that
indicates adequate agreement, Landis and Koch proposed
the following agreement measures for categorical data:
kappa\0.00 represents poor agreement, 0.00–0.20 slight,
0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 substantial
and 0.81–1.00 almost perfect agreement [25]. Accordingly,
Mikami et al. suggested that based on the similarity to the
kappa coefficient, ICC between 0.41 and 0.60 is considered
as moderate correlation; 0.61–0.80 as substantial correla-
tion and[0.80 as a perfect correlation [26]. Chi-square,
Kaplan–Meier and Cox regression tests were applied to test
the association with the standard clinicopathological
parameters, other prognostic biomarkers and outcome of
breast cancer patients. This study adheres to REporting
recommendations for tumour MARKer prognostic studies
(REMARK) criteria [27].
Results
Comparison of Ki67 expression between TMA
and WTS (Protein expression)
Using WTS, Ki67 expression was not normally distributed
(Supplementary Fig. 1A; range 0–99%): the mean per-
centage was 34.8%, while the median percentage was 20%.
Similar to the distribution seen with WTS, Ki67 expression
scored on TMAs was not normally distributed (Supple-
mentary Fig. 1B; range 0–95%): the mean percentage was
21.9%, while the median was 10%. The reproducibility of
Ki67 assessment on TMAs showed that there is a signifi-
cant correlation (p\ 0.001) between the two observers’
scoring. Agreement between the two observers showed an
almost perfect concordance (p\ 0.001) as tested by ICC
intraclass correlation coefficient (ICC = 0.870, 95% con-
fidence interval (CI) = 0.838–0.896). On the other hand,
Ki67 scoring on WTS showed substantial concordance
(ICC = 0.75, 95% CI = 0.670–0.815).
When Ki67 expression was compared between TMA
and WTS, there was a significant correlation when mea-
sured as a continuous variable (p\ 0.001), the Spearman’s
correlations 0.50 with an r2 value of 0.025 (Fig. 1). When
ICC was used, substantial correlation was observed
(ICC = 0.61, p\ 0.001, 95% CI = 0.45–0.71).
To evaluate the reproducibility of Ki67 expression
between WTS and TMA differing cut off points between
platforms were assessed. The highest concordance was
obtained when WTS is 10%. Therefore, for further analy-
sis, the data were dichotomised at 10% as a fixed cut-point
for WTS, which was published previously as the optimal
Breast Cancer Res Treat (2017) 164:341–348 343
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cut-off [28] as well as, and at different cut-points for TMA
to evaluate the reproducibility of the WTS Ki67 expres-
sion: 5, 15, 20, 25 and 30% (Table 1). As shown in Sup-
plementary Fig. 2, higher cut-off values resulted in
misclassification of a higher percentage (62.8%) of cases
assessed on TMAs into the low proliferation group com-
pared with their matched WTS. Conversely, lower cut-off
values resulted in a higher number of cases matching
between the positive cases. However, there was a high
percentage (49.8%) of false-positive cases when assessed
on TMA compared with WTS. A cut-off of 20% for Ki67
expression determined using TMAs seems to give the
highest concordance in both positive and negative groups
with less both false-positive and false-negative Ki67
expressions at 10% determined using WTS.
To test for the impact of cut-points on patient outcome
as an end point, cases were classified based on their Ki67
expression, whether it was low or high, on TMAs and
matched WTS. Therefore, using 10% as a cut-off for Ki67
on WTS and 20% as a cut-off for on TMAs, four groups
were produced. Group one comprised cases with low Ki67
expression on TMAs and their matched WTS, group two
comprised cases with high Ki67 expression on TMAs with
low Ki67 expression on their matched WTS, group three
cases with low Ki67 expression on TMAs with high Ki67
expression on their matched WTS and group four with high
Ki67 expression on TMAs with high Ki67 expression on
their matched WTS. Statistically significant differences
were observed between these groups regarding patients
outcome (Long Rank (LR) = 31.79, p\ 0.001), (Fig. 2).
Interestingly, there was no significant difference between
the groups including high Ki67 expression on WTS
(LR = 0.39, p = 0.52); therefore, they seem to have more
or less similar poor outcome.
Comparison of Ki67 expression between TMA
and WTS in different molecular subclasses
The studied cases were defined with regard to their
molecular class as luminal, which includes ER positive
cases; HER2? and triple-negative (TN), which includes
ER-, PR- and HER2- cases. Assessment of the con-
cordance between Ki67 expression on TMAs and WTS in
molecular subclasses using different cut-points showed that
in TN and HER2? tumours, a cut-off of 20% seemed to
give the highest concordance between WTS and TMAs. In
TN classes, the highest concordance between the positive
cases (91.5%) with the lowest number of false positives
(8.5%) was shown with 20% cut-point using TMA (Sup-
plementary Fig. 3). Similarly, for HER2-positive tumours
20% was the optimal cut-off to classify tumour prolifera-
tion using TMAs where there was 96.2% concordance for
the positive cases and 3.8% false-positive cases (Supple-
mentary Fig. 4). However, in the luminal class, there was
no optimal cut-off for Ki67 determined on TMAs which
was reproducible to the Ki67 scoring on WTS (Supple-
mentary Fig. 5).
Comparison of Ki67 expression on TMA and WTS
with MKI67 mRNA expression
Using the METABRIC cohort, MKI67 mRNA data were
available for 197 and 123 cases matched with WTS and
TMA cases, respectively. The correlation between MKI67
mRNA and Ki67 protein expression determined using 197
cases of WTS was significant, p\ 0.001 and Spearman’s
correlation coefficient = 0.587. Although the correlation
between MKI67 mRNA and 123 cases Ki67 assessed on
TMAs was significant (p\ 0.001), Spearman’s correlation
was less compared with WTS = 0.343. Figure 3 shows the
Fig. 1 Correlation between Ki67 expressions assessed on matched
cases on WTS and TMA
Table 1 Results of classification of the studied cases at different
Ki67 cut-off points (on TMAs) as compared with WTS (10% cut-off)
Ki67 on TMAs Ki67 on WTS (at 10%)
Negative Positive
5% low
High
102 (50.2) 91 (18.1)
101 (49.8) 413 (81.9)
10% low
High
135 (47.9) 147 (52.1)
68 (16.0) 357 (84.0)
15% low
High
157 (43.9) 201 (56.1)
46 (13.2) 303 (86.8)
20% low
High
170 (41.8) 237 (58.2)
33 (11.0) 267 (89.0)
25% low
High
177 (39.1) 276 (60.9)
26 (10.2) 228 (89.8)
30% low
High
181 (37.2) 305 (62.8)
22 (10.0) 199 (90.0)
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correlation between MKI67 mRNA with WTS (r2 = 0.31)
and TMA (r2 = 0.17). In matching 101 BC cases assessed
on both TMA and WTS, MKI67 mRNA expression was
evaluated. Higher significance was observed for Ki67
assessed on WTS (Spearman’s correlation coefficient was
0.529 and p\ 0.001) than on TMA (Spearman’s correla-
tion coefficient was 0.341 and p\ 0.001).
Ki67 and clinicopathological variables and patient
outcome
When assessing Ki67 expression on TMA cores, high
expression of Ki67 ([20%) was significantly associated
with larger tumour size, higher grade, more nuclear pleo-
morphism, higher mitotic scores and less tubule formation
(Supplementary Tables 2 and 3, p\ 0.05). Regarding
patient outcome, univariate survival analysis of Ki67
determined using TMAs showed that a cut-off of 20% was
the most significantly associated with BCSS (LR = 8.76,
p = 0.003, Fig. 4). Furthermore, using Cox regression
analysis, different cut-offs points and the relations with
BCSS were investigated (Table 2). Interestingly, 20%
showed the highest risk on patients’ survival (hazards ratio,
HR = 1.52, 95% CI = 1.15–2.0, p = 0.003). On the other
hand, univariate survival analysis of Ki67 on WTS using
Kaplan–Meier test showed that Ki67 at a cut-off of 10%
was significantly associated with BCSS (LR = 30.1,
p\ 0.001). Furthermore, using Cox regression,[10%
expression of Ki67 gave the highest risk on patients’ sur-
vival (HR = 2.95, 95% CI = 1.96–4.43, p\ 0.001;
Table 3).
Fig. 2 BCSS for Ki67 high/low
groups as defined by Ki67
expression on WTS and TMA at
10 and 20%, respectively
Fig. 3 Correlation between MKI67 mRNA and Ki67 assessed on WTS and TMA
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Discussion
One of the attractive alternatives for using WTS section in
the research field is the use of the TMAs since a large
number of the tissue samples can be simultaneously anal-
ysed under the same experimental conditions. Additionally,
it is a time, resource and cost effective [29, 30]. There is a
mounting evidence indicating the usefulness TMAs in
translational biomarker discovery/validation studies utilis-
ing materials from large scale population-based studies
showing high concordance rates between TMA and WTS
[31]. However, it is imperative to recognise its limitations
especially in interpreting the results of biomarkers with
considerable spatial intra-tumour heterogeneity of expres-
sion. In this study, our results assess different aspects
regarding the comparison between the WTS and TMA
demonstrating its relation to the reproducibility. There is a
significant concordance between the Ki67 expression in the
WTS and TMA. Importantly, concordance was substantial
when continuous data are used (i.e. Ki67%) and much
lower when dichotomised. The latter observation is prob-
ably due to the more tendency of TMA to give lower Ki67
estimates than the whole sections, which we observed in
Ki67 scores of matched cases assessed on WTS and TMAs.
In addition to the intratumoral heterogeneity, this is could
be as a result of using one TMA core. Using more than one
TMA core or a larger core diameter has been suggested to
achieve better representation of the tumour proliferative
fraction. Although Karlsson et al. [32] and Batistatou et al.
[33] showed excellent agreement between TMAs and
whole sections they have used only 10 and 88 cases of BC,
respectively.
Fig. 4 Kaplan Meier plots illustrating BCSS for different Ki67 expression cut-offs assessed on TMAs: a 10%, b 15%, c 20%, d 25% and e 30%
Table 2 Univariate Cox regression analysis for predictors of BCSS
at different Ki67 cut-offs points assessed on TMA
Ki67
cut-offs (%)
p value HR 95% CI
10 0.008 1.496 1.111–2.016
15 0.011 1.440 1.086–1.908
20 0.003 1.519 1.149–2.009
25 0.027 1.379 1.038–1.832
30 0.034 1.370 1.024–1.832
Table 3 Univariate Cox regression analysis for predictors of BCSS
at different Ki67 cut-offs points assessed on WTS
Ki67
cut-offs (%)
p value HR 95% CI
10 \0.001 2.953 1.967–4.432
15 \0.001 1.984 1.451–2.714
20 \0.001 2.050 1.521–2.763
25 \0.001 1.970 1.479–2.623
30 \0.001 1.843 1.392–2.442
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To assess the inter-observer reproducibility of Ki67
assessment, a significant correlation between the scorers
was observed in Ki67 using TMAs. This result is consistent
with results published by an international Ki67 repro-
ducibility study which showed a high intra-laboratory
reproducibility [15]. However, the same study resulted in
only moderate reproducibility between different laborato-
ries, which necessitates a standardised scoring methodol-
ogy. The comparison between the two Ki67 assessed on
WTS and TMA in relation to the clinicopathological
parameters and BC-related biomarkers yielded comparably
similar associations. As expected, high Ki67 was signifi-
cantly associated with larger tumour size, higher tumour
grade, more nuclear pleomorphism and mitotic scores.
Currently, consensus is lacking regarding an optimal
cut-off for Ki67 expression both in the clinical setting and
research settings. This affected the comparison of Ki67
expression in different clinical trials [15]. Ki67 has a sig-
nificant prognostic value over a wide range of cut-offs and
the optimisation of one cut-off is controversial. For
instance, Urruticoechea et al. demonstrated, after evaluat-
ing of 18 studies, the wide range of Ki67 cut-points ranging
from 1% to up to 29%. Accordingly, they concluded that
this varied Ki67 cut-off may be the reason for its restricted
clinical use [21]. One possible explanation for the wide
range of cut-offs could be the absence of standardisation in
the pre-analytical tissue handling, in terms of duration of
ischaemia, time to fixation, dilution and pH of formalin
used in tissue fixation and procedures of antigen retrieval
which largely depend on the pre-analytical phase. Pathol-
ogist’s scoring of the immunohistochemical staining also
has a minor role [34]. Therefore, standardised approaches
in the pre-analytical tissue handling, especially adequate
fixation, are crucial for reliable proliferative fraction assay.
In the current study, we evaluated a wide range of cut-
points in the studied series, and all were significant with
patient outcome as the study end point. The same cut-off
points (10, 15, 20, 25 and 30%) have been examined in the
comparison of Ki67 on WTS and all gave significant
results with BCSS. Interestingly, there are different cut-offs
that have the best correlation with clinicopathological
parameters, biomarkers and patients outcome according to
the type of tissue used, WTS or TMA. 10% seems to be the
best cut-off when the WTS was used, while the statistical
significance was higher using 20% as cut-off when Ki67
was assessed on TMAs. This cut-off of 10% was previously
used in several series published by others for different
purposes. For instance, Pathmanathan et al. evaluated the
utility of Ki67 as a prognostic marker in a series of patients
and emphasised that the highest sensitivity and specificity
of Ki67 cut-off is 10% after evaluation of different cut-offs
using 203 cases as WTS [35]. Furthermore, Shui et al.
using BC cases processed as WTS concluded that
assessment of Ki67 at 10% is a candidate for a standard
method in breast cancer clinical practice [36]. Importantly
and supporting to our results suing TMAs, the St Gallen
has revised the threshold for ‘high’ Ki67 status to C20%
with the option to also use locally specified cut-points [13].
Conclusions
Ki67 expression can be evaluated using WTS and TMA;
however, due to the reported substantial heterogeneity ofKi67
expression in BC the latter should be interpreted with caution.
Assessment ofKi67asa continuousvariablemaybetter reflect
the proliferative status than the predefined dichotomised val-
ues currently in use. A cut-point of 20% inBCwhen assessing
Ki67 on TMAs appears to be optimum both at concordance
with WTS as well as with patients’ outcome.
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